Plain-English translation of NCT06948981 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new treatment designed for adults with certain hard-to-treat blood cancers that have stopped responding to standard therapies. The study will enroll about 46 patients and evaluate how safe the medication is, how well it works, and how the body processes it. Researchers will start with lower doses and gradually increase them to find the best dose while monitoring for side effects.
Some patients with certain blood cancers do not respond well to current standard treatments, leaving them with limited options. This trial exists to explore whether this new treatment could help patients whose cancer has returned or resisted other therapies.
You likely qualify if…
You likely don't qualify if…
As a participant, you will receive as your treatment for this study. The trial includes a dose escalation phase where doses are gradually increased to find the safest and most effective level, followed by an expansion phase where more patients receive the optimized dose. Throughout the study, you will have regular visits for medical exams, blood tests, and monitoring to assess how well the medication is working and track any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China